Browse CXCL10

Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic for monocytes and T-lymphocytes. Binds to CXCR3.

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0001525 angiogenesis
GO:0002237 response to molecule of bacterial origin
GO:0002548 monocyte chemotaxis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0003013 circulatory system process
GO:0003158 endothelium development
GO:0003159 morphogenesis of an endothelium
GO:0006140 regulation of nucleotide metabolic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006949 syncytium formation
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007517 muscle organ development
GO:0007520 myoblast fusion
GO:0007584 response to nutrient
GO:0008015 blood circulation
GO:0009150 purine ribonucleotide metabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009266 response to temperature stimulus
GO:0009314 response to radiation
GO:0009408 response to heat
GO:0009409 response to cold
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0009991 response to extracellular stimulus
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010524 positive regulation of calcium ion transport into cytosol
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010830 regulation of myotube differentiation
GO:0010832 negative regulation of myotube differentiation
GO:0010959 regulation of metal ion transport
GO:0010996 response to auditory stimulus
GO:0014902 myotube differentiation
GO:0016525 negative regulation of angiogenesis
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0031667 response to nutrient levels
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0033273 response to vitamin
GO:0033280 response to vitamin D
GO:0034242 negative regulation of syncytium formation by plasma membrane fusion
GO:0034605 cellular response to heat
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035239 tube morphogenesis
GO:0040017 positive regulation of locomotion
GO:0042118 endothelial cell activation
GO:0042692 muscle cell differentiation
GO:0043270 positive regulation of ion transport
GO:0043949 regulation of cAMP-mediated signaling
GO:0043950 positive regulation of cAMP-mediated signaling
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0045765 regulation of angiogenesis
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0048247 lymphocyte chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051154 negative regulation of striated muscle cell differentiation
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051272 positive regulation of cellular component movement
GO:0051279 regulation of release of sequestered calcium ion into cytosol
GO:0051281 positive regulation of release of sequestered calcium ion into cytosol
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051607 defense response to virus
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060142 regulation of syncytium formation by plasma membrane fusion
GO:0060326 cell chemotaxis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060562 epithelial tube morphogenesis
GO:0061154 endothelial tube morphogenesis
GO:0070098 chemokine-mediated signaling pathway
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090025 regulation of monocyte chemotaxis
GO:0090026 positive regulation of monocyte chemotaxis
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097529 myeloid leukocyte migration
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098542 defense response to other organism
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901509 regulation of endothelial tube morphogenesis
GO:1901623 regulation of lymphocyte chemotaxis
GO:1901739 regulation of myoblast fusion
GO:1901740 negative regulation of myoblast fusion
GO:1902656 calcium ion import into cytosol
GO:1903169 regulation of calcium ion transmembrane transport
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904427 positive regulation of calcium ion transmembrane transport
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008009 chemokine activity
GO:0008201 heparin binding
GO:0008603 cAMP-dependent protein kinase regulator activity
GO:0019207 kinase regulator activity
GO:0019887 protein kinase regulator activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
GO:0048248 CXCR3 chemokine receptor binding
GO:1901681 sulfur compound binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04620 Toll-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL10 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26567139Colon CarcinomaPromote immunity (infiltration)We found that PRC2 components and demethylase JMJD3-mediated histone H3 lysine 27 trimethylation (H3K27me3) repress the expression and subsequent production of Th1-type chemokines CXCL9 and CXCL10, mediators of effector T-cell trafficking. Moreover, the expression levels of PRC2 components, including EZH2, SUZ12, and EED, were inversely associated with those of CD4, CD8, and Th1-type chemokines in human colon cancer tissue, and this expression pattern was significantly associated with patient survival.
26503055Ovarian CarcinomaPromote immunity (infiltration)Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment.
27070705Colorectal CarcinomaPromote immunity (infiltration)While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5.
27022421MelanomaPromote immunity (infiltration)Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte Responses. After treatment with combination therapy, the proportion of MDSCs and Tregs decreased, while the percentage of CXCR3(+)CD8(+) T cells increased.
26109379MelanomaPromote immunity (infiltration)These studies unexpectedly reveal a non-redundant requirement for the CXCR3-CXCL9/CXCL10 axis for CD8+ T cell trafficking within the intravascular space that could not be predicted from static profiling of intratumoral chemokines or their receptors on T cells.
26075911MelanomaPromote immunity (infiltration)Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10 and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade.
26025380Melanoma; Lung CarcinomaPromote immunity (infiltration)Together, our study reveals a negative regulation by STAT3 signaling in T cells on cross-talk between myeloid cells and T cells through IFNγ/CXCR3/CXCL10, which is important for CD8(+) T cells homing to tumors.
25765738MelanomaPromote immunity (infiltration)TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. CXCL10 has been implicated as a critical chemokine supporting T-cell infiltration into the TME.
25754875Colorectal CarcinomaPromote immunity (infiltration)We also demonstrate a selective increase of the chemokines CXCL9 and CXCL10 in Treg-cell-depleted tumors, which were accompanied by accumulation of CXCR3(+) T cells, and increased IFN-γ mRNA expression.
25300859GliomaPromote immunitySTING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Finally, intratumoral administration of a STING agonist (cyclic diguanylate monophosphate; c-di-GMP) improved the survival of glioma-bearing mice associated with enhanced type I IFN signaling, Cxcl10 and Ccl5, and T-cell migration into the brain.
10706701Colorectal adenocarcinomaPromote immunityInjection of AdCMVIP-10 into s.c. tumor nodules derived from the CT26 murine colorectal adenocarcinoma cell line displayed some antitumor activity but it was not curative in most cases. Importantly, intratumoral gene transfer with IL-12 and IP-10 generated a powerful tumor-specific CTL response in a synergistic fashion, while both CD4 and CD8 T cells appeared in the infiltrate of regressing tumors.
27707838Breast CarcinomaPromote immunity (infiltration)We found that DDRD breast tumors were associated with CD4+ and CD8+ lymphocytic infiltration (Fisher's exact test P < .001) and that DDRD cells expressed the chemokines CXCL10 and CCL5 3.5- to 11.9-fold more than DNA damage response-proficient cells (P < .01).
27407095Cervical carcinomaPromote immunityIntravaginal treatment of IL7-Fc, but not native IL7, induces upregulation of chemokines (CXCL10, CCL3, CCL4, and CCL5), cytokines (IFNγ, TNFα, IL6, and IL1β), and an adhesion molecule (VCAM-1) in the genital tract, leading to the recruitment of several leukocytes, including CD4, CD8, γδ T cells, and dendritic cells.
28486109MelanomaPromote immunity (infiltration)Mechanistically, this was due to the absence of CXCL9/10, which we found to be produced by CD103+dendritic cells (DCs) in T?cell-inflamed tumors. Our data indicate that lack of CD103+DCs within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T?cell response, contributing to immune escape.
23481325NeuroblastomaPromote immunityVγ9Vδ2 T lymphocytes were attracted to NB-tumor masses of mice receiving ZOL where they actively modified tumor microenvironment by producing interferon-γ (IFN-γ), that in turn induced CXCL10 expression in NB cells. This study shows that human Vγ9Vδ2 T cells and ZOL in combination inhibit NB growth in vivo and may provide the rationale for a phase I clinical trial in patients with high-risk NB.
19470694Ovarian CarcinomaPromote immunity (infiltration)Furthermore, through synergistic action between IL-17 and interferon-gamma, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor-infiltrating effector T cells. The levels of tumor-infiltrating Th17 cells and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome.
16751375Lung CarcinomaPromote immunitySimilar antitumor and antimetastatic activities of IL-27 were also observed in IFN-gamma knockout mice. Immunohistochemical analyses with Abs against vascular endothelial growth factor and CD31 revealed that B16F10 + IL-27 cells markedly suppressed tumor-induced neovascularization in lung metastases. IL-27 was revealed to directly act on HUVECs and induce production of the antiangiogenic chemokines, IFN-gamma-inducible protein (IP-10) and monokine induced by IFN-gamma. Finally, augmented mRNA expression of IP-10 and monokine induced by IFN-gamma was detected at the s.c.
22333315Breast CarcinomaPromote immunity (infiltration)In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes.
19190335GliomaPromote immunityInterestingly, the antitumor functions were abrogated with CXCL10(-/-) mouse-derived DC1s.
23843024Breast CarcinomaPromote immunity (infiltration)Furthermore, Stat1-deficiency resulted in reduced expression of the T-cell chemotactic factors CXCL9, CXCL10, and CXCL11 in the tumor epithelium.
21324923GliomaPromote immunity (infiltration)Conversely, these mice or ASA-treated wild-type mice displayed enhanced expression of CXCL10 (C-X-C motif chemokine 10) and infiltration of cytotoxic T lymphocytes (CTL) in the TME, consistent with a relief of MDSC-mediated immunosuppression. Antibody-mediated depletion of MDSCs delayed glioma growth in association with an increase in CXCL10 and CTLs in the TME, underscoring a critical role for MDSCs in glioma development. Finally, Cxcl10-deficient mice exhibited reduced CTL infiltration of tumors, establishing that CXCL10 limited this pathway of immunosuppression.
18922917Lymphoma; MelanomaPromote immunity (infiltration)Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Finally, exogenous application of the CXCR3 ligand CXCL10 in the tumor or ectopic expression of CXCL10 by tumor cells increased the numbers of NK cells in the tumors and prolonged NK cell-dependent survival.
21949133Lung CarcinomaPromote immunityIncreased apoptosis, the induction of cytokines (IFN-γ and IL-12) and chemokines (CXCL9 and CXCL10), and the elevation of leukocyte markers (CD11b, CD11c, CD4, and CD8) were detected at tumor sites in C3H/HeN mice but not in C3H/HeJ mice
16980511Breast CarcinomaPromote immunity (infiltration)Mechanical analysis showed that targeted expression of IP-10 in 4T1 tumor cells markedly enhanced the infiltration of tumor-specific T cells into the 4T1-IP-10 tumor. These tumor infiltrating T lymphocytes (TILs) recruited by IP-10 were potent cytolytic killers against 4T1 tumor cells and were able to proliferate and produce high levels of IFN-gamma in response to 4T1 cells. In vivo administration of IP-10-recruited TILs induced vigorous proliferation of these TILs in situ in the 4T1-IP-10 tumor but not in the 4T1-pcDNA3 and parental 4T1 tumors.
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4940.573
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1140.965
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7610.682
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4880.429
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7090.475
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2170.853
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9450.191
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1910.455
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6220.733
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.8830.415
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3140.713
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682301.0520.000992
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL10
Namechemokine (C-X-C motif) ligand 10
Aliases IFI10; IP-10; crg-2; mob-1; gIP-10; INP10; SCYB10; small inducible cytokine subfamily B (Cys-X-Cys), member ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CXCL10.
ID Name Drug Type Targets #Targets
DB04487N-MethylleucineSmall MoleculeCXCL101
DB06116EldelumabSmall MoleculeCXCL101